Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Lung Cancer

  Free Subscription


19.05.2025

3 Ann Oncol
1 Ann Surg Oncol
1 Ann Thorac Surg
3 BMC Cancer
1 Br J Cancer
2 Cancer
2 Cancer Cell
3 Cancer Lett
3 Cancer Res
1 Carcinogenesis
6 Chest
4 Clin Lung Cancer
1 Int J Oncol
1 J Cancer Res Clin Oncol
1 J Clin Invest
8 J Thorac Oncol
11 Lung Cancer
2 Oncogene
1 Oncol Rep
2 Oncologist
3 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Ann Oncol

  1. ROCCO G
    Letter to the Editor: Comments on the study of lung cancer detection by electronic nose analysis of exhaled breath.
    Ann Oncol. 2025 May 12:S0923-7534(25)00196-6. doi: 10.1016/j.annonc.2025.
    PubMed        

  2. SZARPAK L, Pruc M, Bizon M, Olszewski M, et al
    Validation Study of Electronic Nose Detection for Lung Cancer.
    Ann Oncol. 2025 May 12:S0923-7534(25)00197-8. doi: 10.1016/j.annonc.2025.
    PubMed        

  3. LIU J, Shi Y, Yang Y
    Letter Re: Lung cancer detection by electronic nose analysis of exhaled breath: a multi-center prospective external validation study.
    Ann Oncol. 2025 May 12:S0923-7534(25)00195-4. doi: 10.1016/j.annonc.2025.
    PubMed        


    Ann Surg Oncol

  4. SU XE, Lin CL, Wang HG, Jing-Liu, et al
    Development and Validation of a Machine Learning-Based Predictive Model for Postoperative Frailty in Patients with Non-Small Cell Lung Cancer and Its Relation to Early Recovery.
    Ann Surg Oncol. 2025 May 14. doi: 10.1245/s10434-025-17353.
    PubMed         Abstract available


    Ann Thorac Surg

  5. KALTMAN M, Yalamanchili S, Park JA, Weyant MJ, et al
    High catchment areas for lung cancer screening-eligible patients.
    Ann Thorac Surg. 2025 May 13:S0003-4975(25)00414.
    PubMed         Abstract available


    BMC Cancer

  6. CHEN X, Wang K, Liao Y, Zheng C, et al
    Safety and efficacy of rechallenge with immune checkpoint inhibitors and anlotinib in advanced non-small cell lung cancer without targetable driver mutations: a retrospective analysis.
    BMC Cancer. 2025;25:862.
    PubMed         Abstract available

  7. YAO J, Geng Y, Xu J, Zou B, et al
    The impact of EGFR mutation and PD-L1 status on the efficacy of postoperative radiotherapy in stage III-pN2 NSCLC.
    BMC Cancer. 2025;25:858.
    PubMed         Abstract available

  8. ZHENG C, Miao J, Xu L, Cai Y, et al
    Novel PET imaging biomarkers as predictors of postoperative recurrence in lung adenocarcinoma.
    BMC Cancer. 2025;25:874.
    PubMed         Abstract available


    Br J Cancer

  9. THOMAS C, Heathcote L, Sun Y, Callister MEJ, et al
    Cost-effectiveness of one-off upper abdominal CT screening as an add-on to lung cancer screening in England.
    Br J Cancer. 2025 May 14. doi: 10.1038/s41416-025-03043.
    PubMed         Abstract available


    Cancer

  10. HOFF CO, Feng L, Bonini F, Sousa LG, et al
    Survival outcomes of pulmonary metastasis-directed local therapy in adenoid cystic carcinoma.
    Cancer. 2025;131:e35901.
    PubMed         Abstract available

  11. SHOU J, Chen J, Guo Q, Hong W, et al
    Anlotinib in combination with docetaxel for advanced nonsmall cell lung cancer after failure of platinum-based treatment: A phase 1/2 trial.
    Cancer. 2025;131:e35822.
    PubMed         Abstract available


    Cancer Cell

  12. TENG M, Guo J, Xu X, Ci X, et al
    Circular RMST cooperates with lineage-driving transcription factors to govern neuroendocrine transdifferentiation.
    Cancer Cell. 2025;43:891-904.
    PubMed         Abstract available

  13. LI Y, Oser MG
    A circular RNA in neuroendocrine carcinomas.
    Cancer Cell. 2025;43:812-814.
    PubMed         Abstract available


    Cancer Lett

  14. WADE WEI TY, Hsia JY, Yang TY, Huang YX, et al
    Mechanistic Insights into CLNS1A-Mediated Chemoresistance and Tumor Progression in Non-small Cell Lung Cancer.
    Cancer Lett. 2025 May 7:217783. doi: 10.1016/j.canlet.2025.217783.
    PubMed         Abstract available

  15. LUCA AC, Kurnaeva M, John DK, Machtinger M, et al
    Loss of SPHK1 fuels inflammation to drive KRAS-mutated lung adenocarcinoma.
    Cancer Lett. 2025;623:217733.
    PubMed         Abstract available

  16. JIANG M, Zhang K, Wei G, Qi F, et al
    HDAC4 super-enhancer drives CEBPB-mediated TWIST2 transcription to promote chemoresistance in LUAD.
    Cancer Lett. 2025;623:217716.
    PubMed         Abstract available


    Cancer Res

  17. WANG K, Li J, Zhang H, Ma H, et al
    Tobacco Smoking Rewires Cell Metabolism by Inducing GAPDH Succinylation to Promote Lung Cancer Progression.
    Cancer Res. 2025 May 14. doi: 10.1158/0008-5472.CAN-24-3525.
    PubMed         Abstract available

  18. QU T, Song L, Xu J, Lu X, et al
    MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer.
    Cancer Res. 2025 May 14. doi: 10.1158/0008-5472.CAN-23-3748.
    PubMed         Abstract available

  19. TONG X, Lin G, Ji H
    "Dr. Jekyll and Mr. Hyde": AT2 Cells in Lung Regeneration and Tumor Development.
    Cancer Res. 2025;85:1753-1754.
    PubMed         Abstract available


    Carcinogenesis

  20. MA H, Wang G, Miao S, Jin C, et al
    Genetic susceptibility to lung squamous cell carcinoma: new insights on 9q33.2 variants and tobacco smoking.
    Carcinogenesis. 2025;46:bgaf018.
    PubMed         Abstract available


    Chest

  21. BADE B, Faiz SA, Tan M, Baugh AD, et al
    The Impact of Healthcare Disparities on Lung Cancer Screening and Treatment.
    Chest. 2025 May 9:S0012-3692(25)00573-2. doi: 10.1016/j.chest.2025.
    PubMed         Abstract available

  22. JIANG J, Rao Y, Liu C, Chang SJ, et al
    A 7-Year-Old Girl With Multiple Pulmonary Nodules.
    Chest. 2025;167:e161-e165.
    PubMed         Abstract available

  23. TOHMASI S, Eaton DB Jr, Rossetti NE, Heiden BT, et al
    Practice Patterns and Patient Travel Distances for Lung Cancer Surgery in the United States: Analyses of the Veterans Health Administration and the National Cancer Database.
    Chest. 2025 May 8:S0012-3692(25)00563-X. doi: 10.1016/j.chest.2025.
    PubMed        

  24. EZENWANKWO E, Jones C, Nguyen DT, Eberth JM, et al
    Lung Cancer Screening Adherence in Centralized versus Decentralized Screening Programs A Meta-Analysis of U.S. Cohort Studies Among Individuals with Negative Baseline Results.
    Chest. 2025 May 7:S0012-3692(25)00559-8. doi: 10.1016/j.chest.2025.
    PubMed         Abstract available

  25. ABRAHAMS JM, Creekmur B, Lee JS, Amy Liu IL, et al
    Neighborhood-Level Socioeconomic Disadvantage and Adherence to Guidelines for the Evaluation of Patients With Incidentally Detected Pulmonary Nodules.
    Chest. 2025;167:1497-1508.
    PubMed         Abstract available

  26. FENG Y, Kang H, Sood A, Guest DD, et al
    Dietary Pattern, Sputum DNA Methylation, and Lung Health: An Epidemiological Study in People Who Ever Smoked.
    Chest. 2025;167:1333-1345.
    PubMed         Abstract available


    Clin Lung Cancer

  27. OH MS, Garon EB, Lisberg AE, Cummings AL, et al
    Brief Report: The Genomic Landscape of Small Cell Lung Cancer in Never-Smoking Patients.
    Clin Lung Cancer. 2025 Mar 31:S1525-7304(25)00057.
    PubMed         Abstract available

  28. LEE YG, Seo D, Gil HI, Lee H, et al
    Assessment of Lung Cancer Risks Related to Family History in Never-Smokers: A Cohort Study.
    Clin Lung Cancer. 2025 Apr 8:S1525-7304(25)00061.
    PubMed         Abstract available

  29. TOPKAN E, Ozturk D, Selek U
    Comment on: Association of Sarcopenia with Toxicity and Survival in Patients With Lung Cancer, a Multi-Institutional Study With External Dataset Validation.
    Clin Lung Cancer. 2025 Apr 14:S1525-7304(25)00075.
    PubMed        

  30. OHAEGBULAM K, Anderson C, Thompson RF, Mitin T, et al
    Common Medical Comorbidities Influence Pneumonitis Risk After Chemoradiotherapy and Durvalumab Maintenance in Stage III Non-small Cell Lung Cancer.
    Clin Lung Cancer. 2025 Apr 24:S1525-7304(25)00082.
    PubMed         Abstract available


    Int J Oncol

  31. WANG SQ, Zhao BX, Liu Y, Wang YT, et al
    [Corrigendum] New application of an old drug: Antitumor activity and mechanisms of doxycycline in small cell lung cancer.
    Int J Oncol. 2025;66:48.
    PubMed         Abstract available


    J Cancer Res Clin Oncol

  32. WU KW, Deng SY, Zhang XF, Zheng DW, et al
    Thoracoscopy-guided thoracic paravertebral block using dexmedetomidine in combination with ropivacaine for postoperative analgesia after thoracoscopic radical resection of lung cancer: a randomized controlled trial.
    J Cancer Res Clin Oncol. 2025;151:158.
    PubMed         Abstract available


    J Clin Invest

  33. APPADURAI MI, Chaudhary S, Shah A, Natarajan G, et al
    ST6GalNAc-I regulates tumor cell sialylation via NECTIN2/MUC5AC-mediated immunosuppression and angiogenesis in non-small cell lung cancer.
    J Clin Invest. 2025;135:e186863.
    PubMed         Abstract available


    J Thorac Oncol

  34. LINDBERG A, Muhl L, Yu H, Hellberg L, et al
    In Situ Detection of Programmed Cell Death Protein 1 and Programmed Death Ligand 1 Interactions as a Functional Predictor for Response to Immune Checkpoint Inhibition in NSCLC.
    J Thorac Oncol. 2025;20:625-640.
    PubMed         Abstract available

  35. YANAGISAWA A, Shiroyama T, Miyake K, Takeda Y, et al
    Diabetic Ketoacidosis During Lorlatinib Treatment: Case Report.
    J Thorac Oncol. 2025;20:676-679.
    PubMed         Abstract available

  36. WIESWEG M, Alaffas A, Rasokat A, Saalfeld FC, et al
    Treatment sequences in BRAF-V600-mutated non-small cell lung cancer: First-line targeted therapy versus first-line (chemo-) immunotherapy.
    J Thorac Oncol. 2025 May 7:S1556-0864(25)00706.
    PubMed         Abstract available

  37. DE-TORRES JP, Varo N
    The Tree That Let Us See the Forest: The Importance of Comorbidities in Lung Cancer Screening Programs.
    J Thorac Oncol. 2025;20:555-556.
    PubMed        

  38. MREMI A, Ndumbalo J, Chuwa H, Henke O, et al
    Lung Cancer in Tanzania.
    J Thorac Oncol. 2025;20:560-564.
    PubMed        

  39. WANG F, Bao M, Zhu L
    Refining Surgical Decision-Making for Elderly Patients With Lung Cancer: Recognized Risks, Unmet Needs.
    J Thorac Oncol. 2025;20:e62-e63.
    PubMed        

  40. BOSTOCK I, Fox A, Engelhart K, Farjah F, et al
    Response to Letter to the Editor: "Refining Surgical Decision-Making for Elderly With Lung Cancer Patients: Recognized Risks, Unmet Needs".
    J Thorac Oncol. 2025;20:e63-e64.
    PubMed        

  41. JONES SB, Chan C, Filippi AR, Harada K, et al
    Emerging Role of Targeted Therapies Combined with Radiotherapy in Inoperable Stage I-III, Non-Small Cell Lung Cancer (NSCLC): A Review from the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) Subcommi
    J Thorac Oncol. 2025 May 9:S1556-0864(25)00710.
    PubMed         Abstract available


    Lung Cancer

  42. FENG J, Hueniken K, Fan ZJ, Zhan LJ, et al
    Prognostic and predictive effects of TP53 co-mutation in patients with non-small cell lung cancer with rare treatable driver mutations.
    Lung Cancer. 2025;204:108452.
    PubMed         Abstract available

  43. LIN YD, Li HJ, Hong HZ, Qi YF, et al
    Genomic profiling of aggressive pathologic features in lung adenocarcinoma.
    Lung Cancer. 2025;203:108460.
    PubMed         Abstract available

  44. BOSSE Y, Boudreau DK, Saavedra Armero V, Li Z, et al
    Frequency of targetable genetic alterations in resectable lung adenocarcinoma: Results from the LORD project.
    Lung Cancer. 2025;203:108530.
    PubMed         Abstract available

  45. JIN W, Ding Z, Zhang M, Shen L, et al
    The global burden of mesothelioma and its association with asbestos bans, 1990-2021: a population-based study.
    Lung Cancer. 2025;203:108534.
    PubMed         Abstract available

  46. NADAL E, Martin-Martorell P, Benitez JC, Sala MA, et al
    Efficacy and safety of bintrafusp alfa evaluated in a phase II single-arm clinical trial in previously treated advanced pleural mesothelioma.
    Lung Cancer. 2025;203:108545.
    PubMed         Abstract available

  47. QIN Y, Mo Y, Li P, Liang X, et al
    Concurrent immunotherapy improves progression-free survival but increases toxicity in unresectable stage III NSCLC.
    Lung Cancer. 2025;203:108544.
    PubMed         Abstract available

  48. WU K, Bi K, Shen M, Tang C, et al
    Decision-making tree model for distinguishing between benign and malignant subpleural pulmonary lesions based on ultrasonic strain elastography.
    Lung Cancer. 2025;203:108547.
    PubMed         Abstract available

  49. CRESPI V, Delcuratolo MD, Minuti G, Montrone M, et al
    Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancer.
    Lung Cancer. 2025;204:108576.
    PubMed         Abstract available

  50. YANG G, Yoon HI, Lim SM, Hong MH, et al
    Association of thyroid radiation dose with thyroid dysfunction in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy followed by maintenance immunotherapy.
    Lung Cancer. 2025;204:108574.
    PubMed         Abstract available

  51. KAKIUCHI Y, Saruwatari K, Tokito T, Iriki T, et al
    Impact of durvalumab re-administration after moderate symptomatic pneumonitis in locally advanced non-small cell lung cancer.
    Lung Cancer. 2025;204:108578.
    PubMed         Abstract available

  52. GOURLAY E, Banfill K, Merchant Z, Goodley P, et al
    Feasibility, acceptability and clinical outcomes of a real-world, regional lung cancer prehabilitation programme for patients undergoing curative intent radiotherapy.
    Lung Cancer. 2025;204:108572.
    PubMed         Abstract available


    Oncogene

  53. LI S, Lin J, Huang L, Hu S, et al
    STK31 drives tumor immune evasion through STAT3-IL-6 mediated CD8(+) T cell exhaustion.
    Oncogene. 2025;44:1452-1462.
    PubMed         Abstract available

  54. WANG C, Zhang S, Ma B, Fu Y, et al
    Correction: TP53 mutations upregulate RCP expression via Sp1/3 to drive lung cancer progression.
    Oncogene. 2025 May 14. doi: 10.1038/s41388-025-03441.
    PubMed        


    Oncol Rep

  55. YAN Y, Kong X, Jin X, Bu J, et al
    RNA?binding protein MBNL1 regulates tumor growth, chemosensitivity and antitumor immunity in lung adenocarcinoma by controlling the expression of tumor suppressor RNF125.
    Oncol Rep. 2025;54:74.
    PubMed         Abstract available


    Oncologist

  56. XING P, Pu X, Zhou Y, Liu Z, et al
    Efficacy and safety of dacomitinib in treatment-naive patients with advanced NSCLC and brain metastasis: a multicenter cohort study.
    Oncologist. 2025;30:oyaf079.
    PubMed         Abstract available

  57. HU X, Melson JW, Pan SS, Salei YV, et al
    Palliative and end-of-life care in Asian and White patients with metastatic lung cancer.
    Oncologist. 2025;30:oyaf065.
    PubMed         Abstract available


    PLoS One

  58. LI Z, Zhu Z, Wang P, Hou C, et al
    Diagnostic, prognostic, and immunological roles of FUT8 in lung adenocarcinoma and lung squamous cell carcinoma.
    PLoS One. 2025;20:e0321756.
    PubMed         Abstract available

  59. YIN X, Liang HW, Liu Y, Huang W, et al
    Lobectomy versus sublobar resection on survival in patients with stage T1-2N0M0 small cell lung cancer.
    PLoS One. 2025;20:e0324315.
    PubMed         Abstract available


  60. Retraction: Efficient lung cancer detection using computational intelligence and ensemble learning.
    PLoS One. 2025;20:e0324356.
    PubMed        


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.